Roche and Innovent Biologics have agreed a collaboration and exclusive license agreement to develop antibody drug conjugate (ADC) IBI3009 for advanced small cell lung cancer. Under the agreement, the two parties will jointly focus on the early-stage development of the ADC candidate, after which Roche will take over full development. Innovent will receive an upfront […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!